The Rheumatologist
COVID-19 News
You are here: Home / Articles / FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

• By

References

  1. Amgen Inc. News release: FDA approves Prolia (denosumab) for glucocorticoid-induced osteoporosis. 2018 May 15.
  2. Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018 Apr 6. pii: S2213-8587(18)30075-5. [Epub ahead of print]

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »